The More Things Change, the More They Stay the Same
David Gibson,1 Kristen Hsu,1 James Signorovitch,2 and Isabelle Lousada1 1Amyloidosis Research Consortium, Newton, MA, USA; 2The Analysis Group Inc., Boston, MA, USA Amyloid transthyretin (ATTR) amyloidosis is a progressive, debilitating, and ultimately fatal disease caused by deposition of misfolded...
The Inflation Reduction Act: The Devil is in the Details for Patients with Rare Diseases
David Gibson, PhD, CMPP Director of Strategic Programs, Engagement, and Communications Amyloidosis Research Consortium The Inflation Reduction Act (IRA), signed into law on August 16, 2022, tackled a wide range of issues from tax reform, energy security, environmental and...
FDA Approves WAINUA™ (Eplontersen) for Treatment of Hereditary ATTR Amyloidosis Polyneuropathy
BREAKING NEWS: The U.S. Food and Drug Administration has approved AstraZeneca and Ionis’ WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. WAINUA™ (eplontersen) is a Ligand-Conjugated Antisense...
We continue to innovate and improve research and programs to ensure all patients have access to quality care and effective treatment. Your donation will help forge the path to a cure for amyloidosis.
FDA Issues Complete Response Letter for Patisiran for Treatment of Cardiomyopathy of ATTR Amyloidosis
BREAKING NEWS: The U.S. Food and Drug Administration has issued a complete response letter for Alnylam Pharmaceuticals' Patisiran, an investigational RNAi therapeutic for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis. This letter denies approval for the treatment of...
Join our email list to stay up to date on the latest Amyloidosis news.
In this ARC Talks webinar, amyloidosis cardiologist, Dr. Mazen Hanna discusses the function of implantable, electronic devices in cardiac management of amyloidosis patients.
Dr. Hanna provides clarity about which devices exist to assist patients, and the role they serve in heart maintenance. This includes devices for atrial fibrillation management, such as a watchman device, in addition to the indications for a pacemaker or ICD device.
Original Presentation Date:
February 08, 2024
Key Webinar Highlights:
0:00 — Introduction
3:18 — Start of presentation
4:27 — Atrial fibrillation diagram
6:56 — Atrial fibrillation in cardiac amyloidosis
10:02 — Atrial fibrillation: anticoagulation
12:06— Transesophageal echocardiogram (TEE)
13:13 — Intracardiac thrombosis in cardiac amyloidosis
16:08 — CAA occlusion
19:00 — Atrial fibrillation ablation
20:54 — Atrial fibrillation rate control
21:59 — Atrial fibrillation rhythm control
23:06 — Conduction
25:38 — How a pacemaker works
27:57 — Impact of RV pacing on outcomes in ATTR cardiac amyloidosis
28:29 — Cardiac resynchronization therapy in ATTR cardiac amyloidosis
30:17 — Ventricular Arrythmias in cardiac amyloidosis
31:37 — Primary prevention ICD in ATTR cardiac amyloidosis
32:41 — Standard protocol
33:52 — Guidelines for defibrillators
34:37 — MEMs based pressure sensor for monitoring pulmonary artery pressures